Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins
Lantern Pharma got official permission from the government to protect one of its cancer-fighting ideas with a patent, which is like getting a special lock on an invention so only they can use it. This shows the company is making progress on treatments, so watching whether their cancer medicines actually work in real tests will tell you if this protection matters.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.